Showing papers by "Scott P. Runyon published in 2011"
TL;DR: SAR results suggest that the 2-methylbenzoxazole moiety may be replaced with a disubstituted 4-aminophenyl group without loss of activity and an electron-deficient system is generally preferred at the 1,5-naphthyridine moiety for OX1 antagonist activity.
22 citations
Patent•
09 Jun 2011
TL;DR: In this article, the authors describe compounds that are active at neurotensin receptors and represented by the formula: I where the structural variables are defined in the present invention relates to compounds that were used for a variety of therapies, including modulating dopamine transmission, treating Parkinsons disease, preventing a relapse to drug seeking, providing antipsychotic effect, providing neuroprotection, treating pain, treating cancer, and inhibiting cancer progression.
Abstract: The present invention relates to compounds that are active at neurotensin receptors and represented by the formula:(I) where the structural variables are defined herein. The compounds can be used for a variety of therapies, including modulating dopamine transmission, treating Parkinsons disease, preventing a relapse to drug seeking, providing an antipsychotic effect, providing neuroprotection, treating pain, treating cancer, and inhibiting cancer progression.
5 citations